Full text is available at the source.
Management of type 2 diabetes, obesity, or nonalcoholic steatohepatitis with high‐dose GLP‐1 receptor agonists and GLP‐1 receptor‐based co‐agonists
Using high-dose GLP-1 drugs and combined GLP-1 treatments to manage type 2 diabetes, obesity, and fatty liver disease
AI simplified
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are already approved for managing Type 2 diabetes (T2D) and obesity.
- GLP-1RAs may provide clinical benefits for Type 2 diabetes, obesity, and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH).
- Higher doses of GLP-1RAs and novel GLP-1RA-based co-agonists are being evaluated for their potential to reduce glycated hemoglobin (HbA1c) and body weight.
- Ongoing trials are assessing the impact of high-dose GLP-1RAs and multi-hormonal strategies in populations with T2D, obesity, or NASH.
- Available trial findings suggest clinical efficacy and safety of GLP-1RAs, aligning with preclinical observations.
- Expansion of GLP-1R-based drug classes could address the interconnected challenges of T2D, obesity, and NASH.
AI simplified